Intratumoral rIL2-based immunotherapy in B16 melanoma

This publication has 18 references indexed in Scilit:

• Effect of retinoic acid on tumor‐mediated immunologic alterations in mice bearing a variant of the ß16 melanoma
  International Journal of Cancer, 1990
• Interferons alpha and gamma differ in their ability to cause tumour stasis and regression in vivo
  European Journal of Cancer and Clinical Oncology, 1989
• Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients
  Annals of Surgery, 1989
• INTERLEUKINS AND THE IMMUNE SYSTEM 2
  The Lancet, 1989
• Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.
  Journal of Clinical Oncology, 1989
• A new regimen of interleukin 2 and lymphokine-activated killer cells. Efficacy without significant toxicity
  Archives of internal medicine (1960), 1988
• Control of the antitumoral activity of human macrophages produced in large amounts in view of adoptive transfer
  European Journal of Cancer and Clinical Oncology, 1988
• Interleukin-2: Inception, Impact, and Implications
  Science, 1988
• Generation of activated killer cells in tumor-bearing hosts
  International Journal of Cancer, 1987
• Experiences with local chemotherapy and immunotherapy in premalignant and malignant skin lesions
  Cancer, 1970